Studies have shown that by inhibiting the expression of CD38 and increasing NAD+ concentration, SIRT3 concentration can be increased to clear ROS and reduce lipid accumulation, thereby inhibiting the development of non-alcoholic fatty liver disease [32]. Here, CD38 is linked to metabolic dysfunction-associated steatotic liver disease.